How much funding has Aether Therapeutics raised?

Aether Therapeutics has disclosed $4.1M raised across 1 round.

Where is Aether Therapeutics headquartered?

Aether Therapeutics is headquartered in Austin, US.

Aether Therapeutics

Austin, US · Delaware corporation

Find your way into Aether Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Aether Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Aether Therapeutics is a clinical-stage biotech company developing ATX-1209 (oral 6β-naltrexol), a first-in-class µ-opioid receptor modulator designed to reduce opioid-induced physical dependence without affecting pain relief or triggering withdrawal. Its pipeline targets chronic opioid pain dependence, opioid use disorder, neonatal opioid withdrawal syndrome, and acute/cancer pain.

Biotech Healthtech

Founders & leadership

John D HarrisNamed on SEC filing

Eric K OlsonNamed on SEC filing

Wolfgang SadeePresident and CEO

Jon S SaxeNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$4.1M disclosed across 1 round · 2024

▶$4.1MraisedJan 2024 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

John D HarrisExecutive Officer, Director
Eric K OlsonDirector
Wolfgang SadeeDirector
Jon S SaxeExecutive Officer, Director

Offering amount: $6.6M
Amount sold: $4.1M
Minimum investment: $50K
Proceeds to insiders: $150K
Placement agents: Issuer Direct Sales Only
First sale: Jan 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

AltaThera PharmaceuticalsAltaThera develops intravenous antiarrhythmic therapies for treating cardiac conditions including atrial fibrillation and ventricular tachycardia. The company's lead product, Sotalol IV, enables faster patient assessment and potential outpatient discharge compared to oral alternatives.

ADvantage TherapeuticsADvantage Therapeutics is a biopharmaceutical company engaged in therapeutic drug development and clinical research, including NIH/PHS-funded studies evaluating the safety and effectiveness of drugs and treatments.

Areteia TherapeuticsAreteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.

Aera TherapeuticsAera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases. The company focuses on advancing transformative treatments in areas including oncology, rare genetic diseases, and cell therapies.

Companies working in the same space as Aether Therapeutics.

Frequently asked questions

What does Aether Therapeutics do?: Aether Therapeutics is a clinical-stage biotech company developing ATX-1209 (oral 6β-naltrexol), a first-in-class µ-opioid receptor modulator designed to reduce opioid-induced physical dependence without affecting pain relief or triggering withdrawal. Its pipeline targets chronic opioid pain dependence, opioid use disorder, neonatal opioid withdrawal syndrome, and acute/cancer pain.
How much funding has Aether Therapeutics raised?: Aether Therapeutics has disclosed $4.1M raised across 1 round.
Where is Aether Therapeutics headquartered?: Aether Therapeutics is headquartered in Austin, US.